InfiCure Bio is a life science company, which started as a project at Umeå Biotech Incubator (UBI) in 2013. The project was initiated by Prof. Dan Holmberg and Dr. Sofia Mayans based on research conducted in the research group of Prof. Holmberg at the Universities of Umeå and Lund. The company, InfiCure Bio, was established in 2015 and the owners of the company are Dan Holmberg, Sofia Mayans and Åsa Larefalk.
The base of the company is a unique preclinical fibrosis model together with the owners’ competence in the field of inflammation/fibrosis as well as in work with pre-clinical models.
Development of fibrosis in the model is spontaneous, seen in multiple organs (e.g. liver and kidney) and is preceded by chronic inflammation. This resembles many of the human condition that constitute important therapy segments eg chronic liver disease and chronic kidney disease.
The company’s preferred business model is to offer pharmaceutical companies to test their new anti-inflammatory/anti-fibrotic drugs in the unique model. The offer includes set-up, execution, analysis and reporting of results from the effect tests.
The company’s key strengths are:
- A unique preclinical fibrosis model
- Spontaneous development of fibrosis
- 100% reproducibility of the phenotype
- Early onset leading to shortened test protocols
- Competence in the field of inflammation/fibrosis
- Expertise in work with pre-clinical models